GENE ONLINE|News &
Opinion
Blog

Envafolimab, the First Subcutaneously Administered PD-L1 Antibody for HBV Enters Phase IIb Study

by Judy Ya-Hsuan Lin
Share To

Around 257 million people worldwide are affected by the Hepatitis B virus (HBV), of which 70 million are from China. In August, the Phase IIa trial evaluating Ascletis Pharma Inc.’s PD-L1 antibody ASC22 (Envafolimab) demonstrated that it could possibly alleviate the symptoms of chronic hepatitis B (CHB). The promise led to the multi-dose Phase IIb study initiation meeting, held and chaired by Professor Guiqiang Wang, MD, Principal Investigator of the Study.

 

Envafolimab

Known as KN035, ASC22 is a PD-L1 single domain antibody Fc fusion. The drug is convenient for storage at room temperature and delivery by subcutaneous administration. It tackles CHB with a mechanism of action that involves blocking the PD-1/PD-L1 pathway to enhance specific T cell function. This effectively targets HBV because T cell exhaustion is one of the major causes of the disease. In January 2019, Ascletis Pharma Inc. and Suzhou Alphamab Co. announced a strategic collaboration and licensing agreement for the drug to treat Hepatitis B and other viral diseases.

“We are excited about the initiation of this Phase IIb trial in CHB patients,” said Dr. Jinzi J. Wu, Founder, Chairman, and CEO of Ascletis. “As a first-in-class immunotherapy to clinically cure CHB, ASC22 (Envafolimab) has potential to be a cornerstone therapy in various treatment regimens, including combinations with our in-house developed drug candidates and potentially with drug candidates from other industrial leaders.”

“Therapeutic activity has been demonstrated for Envafolimab (KN035) in multiple oncology indications along with a strong safety profile emerging from more than 1000 patient exposure. Although tremendous progress in HBV treatment has been made recently, we are still in an uphill battle to cure this disease,” said Dr. Ting Xu, Chairman of Alphamab. “Because of its superior safety, convenience, and compliance, we are confident that KN035, as a first SubQ PD-L1 antibody, will offer a viable option for CHB patients.”

 

Phase IIa Study

The Phase IIa trial performed a single dose-escalation study with three different levels of ASC22, including 0.3, 1.0, and 2.5 mg/kg. With more than 1,000 participants involved in the study for safety and efficacy tests, all adverse events were grade 1, and no higher grades were observed or reported. The success of ASC22 led Alphamab to submit a new drug application for MSI-H solid tumors. Meanwhile, Shanghai Henlius Pharmaceuticals Co. recently enrolled 44 HBV patients for a Phase II clinical trial to evaluate ASC22’s major competitor, PD-1 inhibitor HLX10.

“Due to its unique immune mechanism, [Envafolimab] may also be used in patients with other chronic viral infections. The safety and convenience of subcutaneous administration [of it] have been reflected to the greatest extent in the treatment of chronic diseases,” Dr. Xu added.

By Judy Ya-Hsuan Lin

Related Article: Ionis Initiates Phase 3 Trials for Familial Chylomicronemia Syndrome Treatment

References
  1. https://en.prnasia.com/releases/apac/subcutaneously-administered-pd-l1-antibody-asc22-envafolimab-is-safe-and-well-tolerated-in-phase-iia-hbv-study-301400.shtml?fbclid=IwAR1eEpHT2zfCgXmUoFUkiZvdMIz_VpAKENSKY_OtUcPTK4-le_yJADy57H0

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Parexel and Japanese Foundation for Cancer Research Collaborate to Boost Oncology Clinical Trials in Japan
2024-01-18
GILEAD LAUNCHES GLOBAL ALL4LIVER GRANT PROGRAM TO HELP ACHIEVE THE WORLD HEALTH ORGANIZATION’S GOAL OF VIRAL HEPATITIS ELIMINATION BY 2030
2023-07-28
2023 ASCO Annual Meeting: Breakthroughs in Cancer Care and Advances in CAR T-cell Therapy
2023-07-11
LATEST
Preventive Medicine for Neurodegeneration on the Rise: New Breakthrough in Routine Blood Testing for Alzheimer’s Disease
2024-05-20
Discrimination Leads to Rapid Aging, Science Shows the Detrimental Effects of this Act
2024-05-17
A New Study has Linked Treatment Resistant Depression to Body Mass Index
2024-05-16
AI Reveals Sex-Related Brain Differences and Precision Medicine Potential
2024-05-16
The EU Sustainability Directive’s Influence on Pharmaceutical Supply Chains
2024-05-15
New UC Berkeley Study Challenges Traditional Views on Lactate and Carbohydrate Metabolism
2024-05-15
First Person to Receive Transplanted Pig Kidney has Died
2024-05-13
EVENT
Scroll to Top